Kiniksa issues updates on abiprubart, KPL-387, mavrilimumab
Kiniksa Pharmaceuticals (NASDAQ:KNSA) plans to discontinue development of its drug abiprubart for the treatment of Sjögren’s ...
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today ...
Investing7h
Jack in the Box stock tumbles after CEO resignation
Shares of Jack in the Box Inc (NASDAQ: JACK) fell by 6.9% following the announcement of Chief Executive Officer Darin Harris's resignation. Harris has decided to ...
Investing9h
Google Cloud's free Gemini coding assistant now available for individuals
Google (NASDAQ: GOOGL) has announced the public preview of a free version of its AI-coding assistant, Gemini Code Assist, for ...
Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa contin ...